Compare DNOW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | VCEL |
|---|---|---|
| Founded | 1862 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2014 | 1996 |
| Metric | DNOW | VCEL |
|---|---|---|
| Price | $16.72 | $44.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $16.67 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 2.4M | 463.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,648,000,000.00 | $276,259,000.00 |
| Revenue This Year | $69.47 | $19.40 |
| Revenue Next Year | $8.01 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.68 | 16.45 |
| 52 Week Low | $10.94 | $28.95 |
| 52 Week High | $17.26 | $49.32 |
| Indicator | DNOW | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 78.01 | 47.47 |
| Support Level | $12.57 | $44.26 |
| Resistance Level | $17.26 | $49.04 |
| Average True Range (ATR) | 0.50 | 1.45 |
| MACD | 0.28 | -0.47 |
| Stochastic Oscillator | 84.38 | 21.56 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.